Skip to main content
SpringerLink
Log in

Expression of p53, PCNA, and C-erbB-2 in Barrett's Metaplasia and Adenocarcinoma

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

We sought to determine if an immunohistochemicalpanel of p53, PCNA, and c-erbB-2 was a useful biomarkerof transformation in Barrett's metaplasia. P53, PCNA,and c-erbB-2 immunohistochemistry was performed on resected Barrett's specimens selected toshow discrete grades of dysplasia and then onprospectively obtained biopsies. In resection specimens,p53 was positive in 36% with no dysplasia, in 30% with low-grade dysplasia, in 85% with high-gradedysplasia, and in 90% of adenocarcinomas. While anevaluation of proliferation throughout the specimen didnot differ between groups, surface proliferation was significantly higher in high-grade dysplasiathan in low-grade or no dysplasia. All high-gradedysplasia specimens were positive for at least onemarker, compared to 44% with no or low-grade dysplasia. C-erbB-2 was only seen in 31% with high-gradedysplasia and in 10% of adenocarcinomas. Prospectively,the panel had a sensitivity of 100%, a specificity of81% and an overall accuracy of 83% in identifying patients who developed high-grade dysplasia orcancer. Thus, overexpression of p53 occurs early in themalignant transformation of Barrett's and increases withhistologic progression, and proliferation at the surface of Barrett's epitheliumincreases with progressive grades of dysplasia. Animmunohistochemical panel of p53 and PCNA is a usefulbiomarker for Barrett's metaplasia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Hesketh PJ, Clapp RW, Doos WG, Spechler SJ: The increasing frequency of adenocarcinoma of the esophagus. Cancer 64:526–530, 1989

    Google Scholar 

  2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287–1289, 1991

    Google Scholar 

  3. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinmeister AR: Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104:510–513, 1993

    Google Scholar 

  4. Naef AP, Savary M, Ozello L: Columnar-lined lower esophagus: An acquired lesion with malignant predisposition. J Thorac Cardiovasc Surg 70:826–835, 1975

    Google Scholar 

  5. Haggitt RC, Tryzelaar J, Ellis RH, Colcher H: Adenocarcinoma complicating columnar epithelial lined (Barrett's) esophagus. Am J Clin Pathol 70:1–5, 1978

    Google Scholar 

  6. Hamilton SR, Smith RRL: The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 87:301–305, 1987

    Google Scholar 

  7. Winters C, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF, et al: Barrett's esophagus: A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92:118–124, 1987

    Google Scholar 

  8. Williamson WA, Ellis FH, Gibb SP, Shahian DM, Aretz HT, Heatley GJ, et al: Barrett's esophagus: Prevalence and incidence of adenocarcinoma. Arch Intern Med 151:2212–2216, 1991

    Google Scholar 

  9. Polepalle SC, McCallum RW: Barrett's esophagus: Current assessment and future perspectives. Gastroenterol Clin North Am 19:733–744, 1990

    Google Scholar 

  10. Spechler SJ, Goyal RK: Barrett's esophagus. N Engl J Med 315:362–371, 1986

    Google Scholar 

  11. Cameron AJ, Ott BJ, Payne WS: The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 313:857–859, 1985

    Google Scholar 

  12. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fanoglio CM, Haggitt RC, et al: Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 14(11):931–968, 1983

    Google Scholar 

  13. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al: Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 19:166–178, 1988

    Google Scholar 

  14. Hameeteman W, Tytgat GNJ, Houthoff HJ, Van Den Tweel JG: Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 96:1249–1256, 1989

    Google Scholar 

  15. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ: An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 105:40–50, 1993

    Google Scholar 

  16. Thompson JJ, Zinsser KR, Enterline HT: Barrett's metaplasia and adenocarcinoma of the esophagus and gastroesophageal junction. Hum Pathol 14:42–61, 1983

    Google Scholar 

  17. Flejou JF, Potet F, Muzeau F, Le Pelletier F, Fekete F, Henin D: Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol 46:330–333, 1993

    Google Scholar 

  18. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, DenBesten L, et al: Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology 94:81–90, 1988

    Google Scholar 

  19. Naef AP, Savary M, Ozello L: Columnar-lined lower esophagus: An acquired lesion with malignant predisposition. J Thorac Cardiovasc Surg 70:826–835, 1975

    Google Scholar 

  20. Hamilton SR, Smith RRL: The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 87:301–305, 1987

    Google Scholar 

  21. McArdle JE, Lewin KJ, Randall G, Weinstein W: Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol 23:479–482, 1992

    Google Scholar 

  22. Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, et al: 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 51:5482–5486, 1991

    Google Scholar 

  23. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318–1327, 1993

    Google Scholar 

  24. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453–456, 1991

    Google Scholar 

  25. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49053, 1991

    Google Scholar 

  26. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:532–536, 1992

    Google Scholar 

  27. Hsu SM, Raine L, Fanger H: Use of avidin-biotin complex in immunoperoxidase techniques: A comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29:577–580, 1981

    Google Scholar 

  28. McKee PH, Hobbs C, Hall PA: Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 23:377–379, 1993

    Google Scholar 

  29. Atkinson M: Barrett's oesophagus—to screen or not to screen? Gut 30:2–5, 1989

    Google Scholar 

  30. Ramel S, Reid BJ, Sanchez CA, Blount PL, Levine DS, Neshat K, et al: Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 102:1220–1228, 1992

    Google Scholar 

  31. Younes M, Lebovitz RM, Lechago LV, Lechago J: p53 protein accumulation if Barrett's metaplasia, dysplasia, and carcinoma: A follow-up study. Gastroenterology 105:1637–1642, 1993

    Google Scholar 

  32. Casson AG, Manolopoulos B, Troster M, Kerksliet N, O'Malley F, Inculet R, et al: Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Am J Surg 167:52–57, 1994

    Google Scholar 

  33. Jones DR, Davidson AG, Summers CL, Murray GF, Quinlan DC: Potential application of p53 as an intermediate biomarker in Barrett's esophagus. Ann Thorac Surg 57:598–603, 1994

    Google Scholar 

  34. Rice TW, Goldblum JR, Falk GW, Tubbs RR, Kirby TJ, Casey G: p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. Thorac Cardiovasc Surg 108:1132–1137, 1994

    Google Scholar 

  35. Symman PJ, Linehan JM, Brito MJ, Filipe MI: p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 173:221–226, 1994

    Google Scholar 

  36. Hardwick RH, Sheperd NA, Moorghen M, Newcomb PV, Alderson D: Adenocarcinoma arising in Barrett's oesophagus: Evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 35:764–768, 1994

    Google Scholar 

  37. Oren M, Maltzman W, Levine AJ: Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1:101–120, 1981

    Google Scholar 

  38. Reich NC, Oren M, Levine AJ: Two distinct mechanisms regulate the levels of a cellular tumor antigen. Mol Cell Biol 3:2143–2150, 1983

    Google Scholar 

  39. Rogel A, Popliker M, Webb CG, Oren M: p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 5:2851–2855, 1985

    Google Scholar 

  40. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351:453–456, 1991

    Google Scholar 

  41. Bartek J, Iggo R, Gannon J, Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5:893–899, 1990

    Google Scholar 

  42. Gannon JV, Greaves R, Iggo R, Lane DP: Activating mutations in p53 produce a common conformational effect: A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602, 1990

    Google Scholar 

  43. Finlay CA, Hinds PW, Tan T-H, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531, 1988

    Google Scholar 

  44. Srivastava S, Tong YA, Devadas K, Zou ZQ, Sykes VW, Chen Y, et al: Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared ‘second hit’ on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome. Oncogene 7:987–991, 1992

    Google Scholar 

  45. Lu Y, Park SH, Thompson TC: Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70:153–161, 1992

    Google Scholar 

  46. Casey G, Lo-Hseuh M, Lopez ME, et al: Growth suppression of human breast cancer cells by introduction of a wild-type p53 gene. Oncogene 6:1791–1797, 1991

    Google Scholar 

  47. Kastan MB, Stone KD, Civin CI: Nuclear oncoprotein expression as function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood 74:1517–1524, 1989

    Google Scholar 

  48. Hall PA, McKee PH, Menage HD, Dover R, Lane DP: High levels of p53 protein in UV irradiated human skin. Oncogene 8:203–207, 1992

    Google Scholar 

  49. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311, 1991

    Google Scholar 

  50. Maltzman W, Czyzyk I: UV irradiation stimulates levels of p53 cellular tumour antigen in nontransformed mouse cells. Mol Cell Biol 4:1689–1694, 1984

    Google Scholar 

  51. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491–7495, 1992

    Google Scholar 

  52. Fritsche M, Haessler C, Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 8:307–318, 1993

    Google Scholar 

  53. Jankowski J, McMenemin R, Yu C, Hopwood D, Wormsley KG: Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression. Gut 33:587–591, 1992

    Google Scholar 

  54. Gillen P, McDermott M, Grehan D, Hourihane DO'B, Hennessy TPJ: Proliferating cell nuclear antigen in the assessment of Barrett's mucosa. Br J Surg 81:1766–1768, 1994

    Google Scholar 

  55. Flejou JF, Paraf F, Muzeau F, Fekete F, Henin D, Jothy S, Potet F: Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: Pathological and prognostic correlations. J Clin Pathol 47:23–26, 1994

    Google Scholar 

Download references

Authors
  1. Michelle A. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle M. Vanbibber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adriana V. Safatle-Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martha R. Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mona F. Melhem
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ulysses Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. James C. Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Young, M.A., Vanbibber, M.M., Safatle-Ribeiro, A.V. et al. Expression of p53, PCNA, and C-erbB-2 in Barrett's Metaplasia and Adenocarcinoma. Dig Dis Sci 42, 2453–2462 (1997). https://doi.org/10.1023/A:1018891923998

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018891923998

Search

Navigation